As filed with the U.S. Securities and Exchange Commission on December 5, 2025 Registration No. 333-290722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identif ...

Core Viewpoint - Zacks Investment Research has initiated coverage of Inspire Veterinary Partners Inc. (IVP) with an Underperform rating due to ongoing financial challenges and structural issues that may hinder shareholder returns in the near to medium term [1] Financial Performance - Inspire Veterinary reported year-to-date net losses of $8 million and an accumulated deficit of $44.3 million as of Q3 2025, raising concerns about its viability as a going concern [2] - The company has negative working capital of $5.9 million and relies on high-cost external financing, with some interest rates exceeding 50% [3] - Revenue declined to $12.2 million in the first nine months of 2025 from $13.3 million in the same period in 2024, indicating that its acquisition-led growth model is not yet yielding consistent revenue growth [4] - The company recorded a negative operating cash flow of $3.6 million in the first nine months of 2025, continuing a trend of cash burn that necessitates ongoing external funding [5] Growth Strategy - Inspire Veterinary aims to expand to 50 hospitals by 2029 and reach $40 million in annual revenues by 2027, with plans to launch an online pet pharmacy in early 2026 to create a new high-margin revenue stream [6] - The company secured up to $10 million in new financing through a convertible preferred offering in August 2025, which enhances near-term liquidity and supports acquisitions [7] - Management targets cash flow breakeven by mid-2026, focusing on improved clinic-level efficiencies and cost control initiatives [7] Market Sentiment - Shares of Inspire Veterinary have significantly declined this year, reflecting investor concerns regarding the company's financial trajectory and strategic execution [8] - The stock trades at levels indicating low market confidence in the company's ability to achieve sustainable growth or profitability in the near term [8] Industry Context - Despite operating in a growing U.S. veterinary services market, Inspire Veterinary faces substantial financial and operational challenges, including reliance on external funding, ongoing losses, and shareholder dilution [9]

Core Insights - A significant portion of U.S. pet owners, 52%, have skipped necessary veterinary care in the past year due to costs, with an additional 15% avoiding vet visits for financial reasons [1][2] - The rising costs of veterinary care have led to an increase in pet insurance coverage, with over 6.4 million pets insured in 2024, marking a nearly 13% increase from 2023 [3] - Veterinary care costs in the U.S. have surged more than 60% since 2014, contributing to the financial strain on pet owners [6] Pet Insurance Market - The average annual premium for accident and illness pet insurance in 2024 is approximately $749 for dogs and $386 for cats, while accident-only policies cost around $193 for dogs and $110 for cats [10] - Pet insurance policies generally fall into three categories: accident-only, accident and illness, and wellness plans, with the latter covering routine expenses [8] - Most insurance policies cover emergency surgeries and treatments for diseases but typically exclude pre-existing conditions [9] Veterinary Costs - Routine checkup costs range from $70 to $174 for dogs and $53 to $124 for cats, while hospitalization can cost between $600 to $3,500 depending on the duration [7] - Emergency surgeries can range from $1,500 to $5,000, highlighting the financial burden pet owners may face [7] Financial Considerations - Pet owners must consider deductibles, reimbursement percentages, and annual limits when selecting insurance policies, with deductibles typically ranging from 10% to 30% [11] - It is essential for pet owners to have sufficient funds to cover vet bills upfront, as reimbursement from insurers can take up to 30 days [16] - Alternatives to pet insurance include self-funding pet healthcare through savings accounts, which can be more financially beneficial if the pet remains healthy [17]

Core Insights - Several companies have emerged as significant losers in the market, experiencing notable price drops and volatility [1][7] Company Summaries - **OneConstruction Group Limited (ONEG)**: The company's stock price fell to $2.35, a decrease of 54.18%. Revenue decreased by 16.2% to $53.2 million for the fiscal year ending March 31, 2025, raising concerns about market sentiment and operational challenges [2][8] - **SCHMID Group N.V. Warrants (SHMDW)**: The stock price decreased by 53.97% to $0.41. The decline from a year-high of $0.9651 to a low of $0.36 may reflect market reactions to company performance or broader industry trends [3][8] - **Taitron Components Incorporated (TAIT)**: The stock price dropped to $1.12, a 46.56% decrease. Despite this, the company declared a quarterly cash dividend of $0.035 per share, aiming for an annual dividend of $0.14 per share. The decline from a high of $5.1 to a low of $1.11 may be influenced by operational challenges or shifts in demand within the technology sector [4][8] - **Inspire Veterinary Partners, Inc. (IVP)**: The company's stock price decreased by 39.99% to $0.46. However, it reported a 7% increase in total revenues to $4.3 million and a 27% reduction in net losses for the third quarter of 2025. The downturn from a high of $6.3 to a low of $0.419 could be attributed to market sentiment or competitive pressures [5][8] - **Republic Power Group Limited Class A Ordinary Shares (RPGL)**: The stock price fell to $0.51, a 38.97% drop. The company closed its initial public offering on October 15, 2025, with shares priced at $4.00 each. The decline from a year-high of $5.19 to a low of $0.4551 suggests challenges that may include market competition or operational hurdles [6][8]

More pricing transparency in the UK veterinary industry is welcome, but don't expect lower pet-care bills, writes @chrismbryant (via @opinion) https://t.co/O8Nai4YgCo ...

Market Regulation - UK antitrust regulator calls for more competition and a regulatory overhaul of the veterinary industry [1] - The regulator stopped short of proposing broader pricing controls [1] Company Performance - Pets at Home and CVS shares surged following the regulator's announcement [1]

Core Insights - IDEXX Laboratories, Inc. is valued at a market cap of $50.7 billion and is a leader in veterinary diagnostics and software solutions [1] - The company is set to announce its fiscal Q3 earnings for 2025, with analysts projecting a profit of $3.14 per share, reflecting a 12.1% increase from the previous year [2] - Analysts expect IDEXX to report an EPS of $12.61 for the current year, which is an 18.2% increase from fiscal 2024, with further growth anticipated [3] Financial Performance - In the last fiscal quarter, IDEXX reported quarterly revenue of $1.1 billion, a 10.6% year-over-year increase, and earnings per share of $3.63, a 48.8% increase from the same quarter last year [5] - The company raised its fiscal 2025 EPS guidance to a range of $12.40–$12.76, indicating strong profitability and reinforcing investor confidence [5] Stock Performance - IDEXX shares have increased by 33.2% over the past year, outperforming the S&P 500 Index's return of 13.4% and the Health Care Select Sector SPDR Fund's decline of 8% [4] - Wall Street analysts have a "Moderate Buy" rating on IDEXX, with a mean price target of $722.36, suggesting a potential upside of 13.4% from current levels [6]

Core Insights - Inspire Veterinary Partners, Inc. is experiencing positive client growth and momentum compared to previous years [1] - The company is positioned for success and has returned to a growth trajectory [1] Company Achievements - Inspire Veterinary Partners has highlighted key achievements that demonstrate progress year to date [1] - The leadership, including Chairman and CEO Kimball Carr, emphasizes the company's improved positioning for future success [1]

| Nevada | 8900 | 85-4359258 | | --- | --- | --- | | (State or jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification No.) | 780 Lynnhaven Parkway Suite 400 Virginia Beach, Virginia 23452 As filed with the U.S. Securities and Exchange Commission on September 19, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT ...

Core Insights - Zomedica Corp. is showcasing its TRUVIEW digital cytology microscope in a webinar series aimed at innovation in veterinary care [1] - The TRUVIEW microscope enhances digital cytology and hematology practices by enabling rapid and high-quality image capture and interpretation [1] Company Overview - Zomedica is a veterinary health company focused on advanced diagnostic and therapeutic solutions for companion and equine animals [1] Industry Impact - The introduction of the TRUVIEW microscope represents a significant advancement in veterinary diagnostic technology, potentially improving the efficiency and accuracy of veterinary practices [1]